FDA THRESHOLD: LOWER-RISK BIOTECH INVESTING Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : FDA THRESHOLD: LOWER-RISK BIOTECH INVESTING

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: opalapril who wrote ()	10/6/1999 8:46:00 AM
From: opalapril	of 75

General biotech investment advice. (Thanks to someone on the INCY thread) <<Caroline Copithorne: a) The rally in the Bioetch sector has recently broadened to include mid-cap as well as small-cap biotechs. The key remains picking a company with later stage products, a healthy balance sheet, and strong pharmaceutical support. b) To get an idea of the likelihood for FDA approval for a drug, you need to look at the clinical data. Companies generally present earlier stage data (Phase I or II) at scientific meetings, which gives you a good idea what the possibility of approval is. If you can't attend these meetings and are not able to access the data, you need to find out if the drug under review is a completely new category with a novel mechanism (higher risk) or is it an improvement over an existing category of drugs (lower risk). c) As a general rule, Phase III means about a 50-75% chance for approval (Phase I is 10-25%, Phase II is 25-50%).>> To read the whole interview: multexinvestor.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next